Sjogren's Disease: What You Need to Know

Created by Mahiar Rabie, MD, MS using current medical evidence and guideline-based sources. It is intended to inform and educate, not to replace the advice, diagnosis, or treatment of a qualified physician.

Overview

What is Sjogren's disease?

Sjogren's disease is a chronic systemic autoimmune condition in which the immune system attacks the glands responsible for producing moisture, primarily the lacrimal glands that make tears and the salivary glands that make saliva. The result is persistent dry eyes and dry mouth. But Sjogren's is far more than a dryness condition. For many patients, it causes debilitating fatigue, widespread pain, joint inflammation, nerve symptoms, and involvement of the lungs, kidneys, skin, and other organs.[1]

It is worth knowing from the start that Sjogren's looks different in different people. Some patients have mostly dryness; others have little dryness but significant fatigue, joint pain, or organ involvement. Dryness alone does not define the severity of the disease.

Sjogren's is estimated to affect somewhere between 0.01 and 0.09 percent of the population, though it is widely believed to be underdiagnosed. It is one of the most common systemic autoimmune diseases overall. The condition affects women at roughly nine times the rate of men and most often appears in women in their 40s and 50s, though it can occur at any age.[3]

Primary vs. associated Sjogren's. When Sjogren's occurs on its own, without another underlying autoimmune disease, it is called primary Sjogren's. When it develops alongside another rheumatic disease, such as rheumatoid arthritis or lupus, it is called associated Sjogren's. The term "secondary Sjogren's" was historically used for the associated form, but this language is falling out of favor because it implies Sjogren's is a less important or later complication, which is often not the case. Both forms are treated similarly, and Sjogren's is not automatically less severe when it accompanies another condition.[1]

One of the most important things to understand about Sjogren's is that the disease exists on a wide spectrum. Some people have mild sicca symptoms, meaning dryness of the eyes and mouth, without much else. Others have significant systemic involvement affecting multiple organs. Most patients fall somewhere in between and may move along this spectrum over time.[2]

Why does it take so long to diagnose? Sjogren's is frequently misdiagnosed, often initially labeled as fibromyalgia, depression, dry eye syndrome, or even lupus or rheumatoid arthritis because positive ANA and rheumatoid factor tests are common in all of these conditions. Dryness is often dismissed as aging or medication side effects. Anti-Ro/SSA antibodies, the most specific serologic marker for Sjogren's, may not be ordered unless a clinician suspects the diagnosis. The average time from symptom onset to confirmed diagnosis is more than three years.[1,3]

Clinical Features

Symptoms of Sjogren's disease

Sjogren's symptoms fall into two broad categories: exocrine gland symptoms (dryness of the eyes, mouth, and other mucosal surfaces) and extraglandular symptoms (everything outside the glands). Nearly all patients experience some form of sicca, but fatigue and pain are often the most disabling complaints.[2]

Dry eyes (keratoconjunctivitis sicca)

A gritty, sandy, or burning feeling in the eyes, often worse in the evenings. Patients may describe irritation, light sensitivity, blurred vision, or a stringy mucus discharge on waking. Dryness can be severe even when symptoms feel mild, which is a distinctive feature of Sjogren's-related eye disease.[2]

Dry mouth (xerostomia)

Persistent dryness that makes it hard to eat dry foods, speak for extended periods, or wear dentures comfortably. Salivary hypofunction leads to a significantly increased rate of dental cavities, particularly at the gumline and edges of teeth. Oral candidiasis is also common.[2]

Fatigue and brain fog

One of the most disabling and least understood aspects of Sjogren's. Fatigue is not simply tiredness; it can be profound and unpredictable. Brain fog, meaning difficulty concentrating, word-finding problems, and cognitive slowness, is very common and often does not correlate with how active the inflammation appears on lab tests.[5]

Joint pain and arthritis

About half of primary Sjogren's patients report joint pain, with or without signs of active synovitis. The arthropathy is usually symmetric, intermittent, and nonerosive on imaging, though a subset of patients with anti-CCP antibodies may develop more inflammatory and erosive arthritis.[5]

Salivary gland swelling

Enlargement of the parotid glands (the large glands in front of the ears) occurs in up to half of patients at some point. Swelling may be intermittent or persistent, and glands are usually firm and nontender. Persistent unilateral swelling, especially if hard or nodular, warrants evaluation for lymphoma.[2]

Neuropathy

Peripheral neuropathy affects roughly 10 percent of Sjogren's patients. Small fiber neuropathy, which causes burning, tingling, or numbness in the feet and hands without showing up on standard nerve conduction studies, is particularly underrecognized. Neuropathic symptoms can precede the Sjogren's diagnosis by years.[5]

Lung involvement

About 10 to 20 percent of patients develop clinically significant lung disease, most commonly interstitial lung disease. A dry, persistent cough is often the first sign. Upper and lower airway dryness can mimic asthma or recurrent bronchitis, and the correct underlying diagnosis is often missed.[5]

Skin and other dryness

Dry skin (xerosis) occurs in roughly a third to two-thirds of patients and causes itch and scaling, most often on the legs. Vaginal dryness and dyspareunia are common and often undertreated. Nasal dryness, recurrent sinusitis, and dry cough from airway involvement are also frequent complaints.[5]

Fibromyalgia overlap. Fibromyalgia is present in 15 to 30 percent of people with primary Sjogren's disease. This is important because fibromyalgia does not respond to immunosuppressive treatment, while the inflammatory aspects of Sjogren's may. Distinguishing between Sjogren's-driven symptoms and fibromyalgia-driven symptoms is one of the more complex aspects of managing this disease, and both can coexist in the same patient.[5]

Thyroid disease. Autoimmune thyroid disease, including Hashimoto's thyroiditis, occurs at higher rates in people with Sjogren's disease. Fatigue that does not respond to standard Sjogren's management should prompt thyroid testing, since hypothyroidism can closely mimic or worsen Sjogren's-related exhaustion.[5]

Getting Diagnosed

How Sjogren's is diagnosed

There is no single test that confirms Sjogren's disease. Diagnosis usually relies on a combination of symptoms, objective dryness testing, and evidence of autoimmunity, such as anti-Ro/SSA antibodies or a positive lip biopsy, while ruling out other causes. Not everyone with dry eyes or dry mouth has Sjogren's, and not everyone with Sjogren's looks the same.[3]

What prompts the workup. Sjogren's should be suspected when someone has daily, persistent dry eyes or dry mouth for three months or more, unexplained dental decay in an otherwise careful patient, recurrently swollen salivary glands, or lab results showing positive ANA, anti-Ro/SSA, or rheumatoid factor without another clear explanation. Before attributing dryness to Sjogren's, it is worth reviewing all current medications, as anticholinergic drugs, antihistamines, antidepressants, diuretics, and many other common medications are among the most frequent causes of dry mouth and dry eye in the general population. Some patients are first evaluated for Sjogren's because of fatigue, neuropathy, or interstitial lung disease, even before sicca symptoms are prominent.[3]

Eye testing. Formal ophthalmology evaluation is recommended for all patients with suspected Sjogren's. This includes the Schirmer test, which measures how much the filter paper strip wets over five minutes; less than 5mm indicates aqueous tear deficiency. Ocular surface staining with fluorescein and lissamine green dyes reveals areas of epithelial cell damage on the cornea and conjunctiva. These tests are more informative than a standard eye exam.[3]

Salivary testing. Salivary flow rates can be measured by having a patient collect saliva over a set time period. Salivary gland ultrasound is a promising and increasingly used adjunctive tool at some centers, showing characteristic abnormalities in gland structure. Availability and interpretation vary, and it does not yet replace the lip biopsy in patients without anti-Ro/SSA antibodies.[3]

The lip biopsy. A labial minor salivary gland biopsy (commonly called a lip biopsy) remains one of the most important diagnostic tests, particularly in patients without anti-Ro/SSA antibodies. Under local anesthesia, several tiny glands are removed from the inside of the lower lip. A pathologist then looks for focal lymphocytic sialadenitis, a specific pattern of immune cell infiltration around gland ducts. This biopsy also provides prognostic information, as certain findings are associated with a higher risk of lymphoma. Persistent numbness of the lip occurs in up to 6 percent of patients and should be discussed in advance.[3]

Important note on the ANA test. The ANA test should not be used as a primary screening test for Sjogren's. Some patients with Sjogren's have a negative ANA but still have anti-Ro/SSA antibodies. If Sjogren's is suspected based on symptoms, anti-Ro/SSA should be ordered directly, regardless of ANA result. A positive ANA alone does not make a diagnosis of Sjogren's, as it is common in many autoimmune conditions and in healthy people.[3]

Ruling out mimics. Several conditions can look like Sjogren's and need to be excluded. These include hepatitis C infection (which can cause sicca symptoms, positive RF, cryoglobulinemia, and even salivary gland involvement), IgG4-related disease (which causes gland enlargement with a distinct histopathology), sarcoidosis, HIV, and age-related dryness. Hepatitis C testing is recommended in all patients being evaluated for Sjogren's.[3]

The 2016 ACR/EULAR classification criteria. These are the current research classification criteria for primary Sjogren's, based on a weighted scoring system. Patients who score four or more points qualify for classification, based on anti-Ro/SSA positivity, lip biopsy result, Schirmer test, salivary flow rate, and ocular surface staining scores. These criteria were developed for research purposes and are not a diagnostic checklist, but they help systematize the evaluation. A clinician can and does diagnose Sjogren's in patients who do not formally meet the classification threshold if the overall picture is convincing.[3]

Laboratory Testing

Lab tests in Sjogren's disease

No single lab test diagnoses or measures disease activity in Sjogren's. Clinicians interpret a panel of tests together with the clinical picture. Here is what the key tests mean for patients.

Test	What it means in Sjogren's
Anti-Ro/SSA antibodies	The most important serologic marker. Present in 60 to 80 percent of primary Sjogren's patients. A positive result is required for the 2016 classification criteria. These antibodies are also associated with more severe glandular inflammation and a higher rate of extraglandular disease. They are not specific to Sjogren's and are also found in lupus.[4]
Anti-La/SSB antibodies	Less common and less specific than anti-Ro/SSA. Most patients with anti-La/SSB also have anti-Ro/SSA. Anti-La/SSB alone (without anti-Ro/SSA) is not sufficient to diagnose Sjogren's and should be interpreted with caution. Having both antibodies together is associated with more severe disease.[4]
ANA	Positive in roughly two-thirds of primary Sjogren's patients but negative in 15 to 40 percent. The ANA should not be used to screen for or rule out Sjogren's. Some patients have positive anti-Ro/SSA with a negative ANA. A speckled pattern is most common, but a centromere pattern suggests a specific Sjogren's subset with features overlapping with scleroderma.[4]
Rheumatoid factor (RF)	Present in 40 to 70 percent of Sjogren's patients. In Sjogren's, a positive RF does not mean RA, as the vast majority of these patients lack anti-CCP antibodies, which is the more specific RA marker. Elevated RF in Sjogren's is associated with more severe disease and a higher risk of developing lymphoma.[4]
Complement (C3, C4)	Low complement, particularly low C4, is associated with more systemic disease activity and a significantly increased risk of lymphoma. Hypocomplementemia combined with cryoglobulinemia and purpura is a high-risk triad that warrants close monitoring.[1]
Cryoglobulins	Present in roughly 10 to 15 percent of primary Sjogren's patients, usually mixed monoclonal type II. Associated with cutaneous vasculitis, kidney involvement, neuropathy, and a substantially elevated lymphoma risk. When present alongside hypocomplementemia and purpura, this triad is a serious prognostic marker.[5]
CBC with differential	Leukopenia occurs in 12 to 22 percent, and mild anemia in about 20 percent of patients. Cytopenia in Sjogren's can reflect active disease but, if new or worsening, should raise concern for underlying lymphoma. The white count may fluctuate between normal and low during the disease course.[5]
ESR and CRP	ESR is often elevated in Sjogren's as a reflection of high immunoglobulin levels, not necessarily active inflammation. CRP may be normal or mildly elevated in uncomplicated Sjogren's; a markedly elevated CRP should prompt investigation for infection, serositis, or interstitial lung disease.[1]
Urinalysis with protein:creatinine ratio	Kidney involvement in Sjogren's is usually tubulointerstitial nephritis, which can cause renal tubular acidosis. Hypokalemia and low serum bicarbonate may be the first clues. Proteinuria on dipstick testing may miss the low-molecular-weight proteins characteristic of tubular disease; a spot protein:creatinine ratio is more sensitive.[1]
Serum protein electrophoresis (SPEP)	Hypergammaglobulinemia is common in Sjogren's, often polyclonal, reflecting immune activation. A monoclonal protein, particularly IgM kappa, is associated with a higher risk of lymphoma development and warrants closer surveillance.[1]
TSH and vitamin B12	Both should be checked in patients with significant fatigue, as autoimmune thyroid disease and B12 deficiency are more common in Sjogren's patients and are both treatable causes of exhaustion that can be mistaken for Sjogren's-related fatigue.[1]

The high-risk lab triad. Cryoglobulinemia, hypocomplementemia (especially low C4), and palpable purpura together in a Sjogren's patient represent a significantly elevated risk of non-Hodgkin lymphoma and serious systemic complications. If you have had any of these lab findings flagged, ask your rheumatologist what they mean for your monitoring plan.[5]

Management

Treatment of Sjogren's disease

There is currently no FDA-approved disease-modifying therapy specifically for Sjogren's disease, though several drugs are in clinical trials. Treatment is targeted at the specific manifestations each patient has. Patients with sicca symptoms alone are managed with local and topical measures; systemic immunosuppressive therapy is reserved for those with significant extraglandular involvement.[1]

Care is best provided by a multidisciplinary team that typically includes a rheumatologist, ophthalmologist, and a dentist or oral medicine specialist familiar with dry mouth management.[1]

All Patients

Artificial tears, lubricating eye drops, and ocular surface care

Preservative-free artificial tears are a cornerstone of dry eye management and should be used throughout the day as needed. More viscous gels and ointments are useful at night. Avoiding medications with anticholinergic effects (many antihistamines, some antidepressants, bladder medications, and over-the-counter sleep aids) is important, as these can significantly worsen dryness. Cyclosporine eye drops (Restasis) and lifitegrast (Xiidra) are prescription options that work on the underlying ocular surface inflammation and can provide meaningful benefit in moderate to severe dry eye.[1]

All Patients

Dry mouth management and dental care

Sipping water frequently, using sugar-free stimulants such as xylitol gum and lozenges, avoiding alcohol and caffeine, and using room humidifiers all help. Artificial saliva products provide temporary lubrication. Meticulous dental hygiene is non-negotiable; prescription-strength fluoride (1.1% sodium fluoride gel used nightly) is recommended for most Sjogren's patients because of dramatically elevated cavity risk. Dental visits every 3 to 6 months rather than annually are often appropriate. Prompt treatment of oral candidiasis, which occurs in over a third of patients, is important.[6]

Moderate Dryness

Pilocarpine and cevimeline (muscarinic agonists)

These prescription medications stimulate residual salivary and lacrimal gland function. They work only if there is still functional gland tissue remaining, which is why they are more effective earlier in the disease. Pilocarpine is typically dosed four times daily; cevimeline three times daily, and may be better tolerated. Side effects include sweating, flushing, and increased urinary frequency. These agents may also improve nasal and vaginal dryness as a secondary benefit. They should be avoided in patients with uncontrolled asthma or significant heart disease.[6]

Systemic Disease

Hydroxychloroquine (Plaquenil)

Used for joint pain, fatigue, and constitutional symptoms in Sjogren's, modeled on its well-established role in lupus. It does not meaningfully improve sicca symptoms based on randomized trial data, but it can help with arthralgias, elevated inflammatory markers, and hypergammaglobulinemia. Dosing follows similar weight-based principles as in lupus, and the same ophthalmology screening for retinal toxicity applies. Smoking significantly reduces its effectiveness.[1]

Systemic Disease

Methotrexate and other conventional DMARDs

Methotrexate is used for inflammatory arthritis, persistent salivary gland swelling, and cutaneous manifestations. Azathioprine, mycophenolate mofetil, and leflunomide are used for more significant organ involvement such as lung disease, kidney disease, or vasculitis. As in other rheumatic diseases, these agents require regular lab monitoring and take weeks to months to reach full effect. The evidence base for these agents in Sjogren's is more limited than in RA or lupus, but they are widely used based on clinical experience and indirect evidence.[1]

Severe Disease

Rituximab and other biologics

Rituximab, an anti-CD20 antibody that depletes B cells, is used for serious extraglandular manifestations including cryoglobulinemic vasculitis, peripheral neuropathy, severe arthritis, and autoimmune cytopenias. Randomized trials targeting dryness and fatigue as primary outcomes have been largely negative, but registry data and open-label studies show benefit for specific organ manifestations. Several newer targeted therapies (including ianalumab, remibrutinib, and telitacicept) have shown positive results in phase 2 trials and are being evaluated in larger studies.[1]

Lifestyle

Smoking cessation, diet, and exercise

Smoking worsens dry mouth and dry eye, reduces the effectiveness of hydroxychloroquine, and may worsen small airway disease in Sjogren's. Omega-3 fatty acids (from fish oil or flaxseed oil) may benefit dry eye and inflammatory joint pain, and Mediterranean-style eating patterns have shown some benefit in cohort studies. Low-impact aerobic exercise is the best-supported intervention for Sjogren's-related fatigue and is recommended as first-line therapy before escalating to systemic drugs.[1]

Managing fatigue specifically. Fatigue in Sjogren's is multifactorial. Before attributing it to disease activity, clinicians should check for treatable contributors including hypothyroidism, vitamin D deficiency, vitamin B12 deficiency, sleep apnea, anemia, depression, and fibromyalgia. Exercise and cognitive behavioral therapy are the best-supported interventions for Sjogren's-related fatigue in the absence of active systemic inflammation. Hydroxychloroquine is sometimes used when fatigue occurs alongside inflammatory joint symptoms or other inflammatory features, but it is not reliably effective for fatigue in isolation based on current trial data.[1]

Long-term Care

Monitoring in Sjogren's disease

Sjogren's requires ongoing monitoring even when symptoms feel stable, because some of the most serious complications, including kidney disease and lymphoma, can develop without dramatic warning signs. The monitoring plan depends on which organ systems are involved and what risk factors are present.

What is monitored	Why it matters
Complete blood count	Leukopenia and anemia are common and can reflect disease activity. New-onset cytopenia, particularly if progressive, should raise concern for lymphoma development.[1]
Complement levels (C3, C4)	Persistent low complement, especially C4, is associated with both systemic disease activity and elevated lymphoma risk. Trending complement levels over time is more informative than a single measurement.[1]
Urine testing	Kidney involvement in Sjogren's (most often tubulointerstitial nephritis) can be silent. Urine protein:creatinine ratio is more sensitive than dipstick for detecting tubular proteinuria. Electrolytes should be checked periodically for signs of renal tubular acidosis.[1]
Immunoglobulins and SPEP	Evolving monoclonal proteins, particularly IgM kappa, can be an early sign of lymphoma. Annual monitoring of serum immunoglobulins and protein electrophoresis is reasonable in most patients.[1]
Salivary gland examination	New, persistent, or asymmetric gland swelling, especially if hard or nodular, requires imaging and possible biopsy. Swelling that was previously intermittent and has become persistent is a particular red flag for lymphoma.[2]
Pulmonary function and chest imaging	Because Sjogren's can affect the lungs, clinicians often consider baseline chest imaging and sometimes pulmonary function testing, especially when respiratory symptoms or risk factors are present. Patients with cough or dyspnea should have more formal evaluation including high-resolution CT. Lung disease in Sjogren's can progress slowly and may be undertreated if not actively sought.[5]
Thyroid function (TSH)	Autoimmune thyroid disease is more common in Sjogren's patients. Periodic TSH testing is warranted, particularly in patients with worsening fatigue or weight changes.[5]
Eye exams	Regular ophthalmology follow-up for disease monitoring and adjustment of dry eye treatment. In patients on hydroxychloroquine, retinal toxicity screening follows the same AAO guidelines as in lupus: baseline screening, then ongoing surveillance guided by dose, duration, and individual risk factors.[1]
Dental exams	Every 3 to 6 months for most patients. The dramatically accelerated cavity rate in Sjogren's requires active dental surveillance, not just annual checkups.[6]

Important Risk

Lymphoma risk in Sjogren's disease

Sjogren's disease carries the highest lymphoma risk of any autoimmune condition. The lifetime risk of developing non-Hodgkin lymphoma is estimated at 5 to 10 percent, which is 5 to 44 times higher than in the general population. This sounds alarming, and it is worth understanding clearly, because it shapes how Sjogren's should be monitored, but it should also be kept in context: most people with Sjogren's will never develop lymphoma.[5]

The most common type of lymphoma in Sjogren's is extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), most often arising in the parotid glands. The most common lymphoma type is an indolent MALT lymphoma, most often involving the parotid glands. It behaves very differently from aggressive lymphomas, and most patients with parotid MALT lymphoma can be managed with rituximab or watchful waiting in selected cases.[5]

The transition from chronic glandular inflammation to lymphoma usually unfolds over years, not weeks or months. The biology of this process is well understood: chronic B cell stimulation in the salivary glands eventually creates conditions for malignant transformation, especially in patients with persistent germinal center formation.[5]

Warning signs that require prompt evaluation. Contact your rheumatologist promptly if you notice any of the following: a parotid or other salivary gland that was previously intermittently swollen has now been persistently enlarged for 8 or more weeks; the gland feels hard or has nodular areas; there is regional lymph node swelling; you have developed unexplained weight loss, drenching night sweats, or persistent fever. These symptoms do not necessarily mean lymphoma, but they always require investigation.[2]

Who is at higher risk? Certain clinical and lab findings identify patients with substantially elevated lymphoma risk. These include persistent chronic parotid swelling, palpable purpura from cutaneous vasculitis, cryoglobulinemia, hypocomplementemia (especially low C4), elevated rheumatoid factor, a monoclonal IgM kappa protein, lymphopenia, and higher focus scores on lip biopsy. Patients with several of these features need closer surveillance than those without them.[5]

Evaluation for suspected lymphoma requires imaging (MRI or CT of the neck) and biopsy, either excisional or ultrasound-guided core needle biopsy. Fine needle aspiration alone is insufficient for lymphoma diagnosis because it misses the architectural features needed to classify the tumor type.[1]

Family Planning

Sjogren's disease and pregnancy

For most women with Sjogren's, pregnancy outcomes are broadly similar to those of the general population. However, women with high-titer anti-Ro/SSA antibodies face a specific and important pregnancy risk: congenital heart block in the baby.[5]

Congenital heart block. Anti-Ro/SSA antibodies (particularly anti-Ro52) can cross the placenta and interfere with the developing fetal cardiac conduction system, causing neonatal lupus and, in rare but serious cases, complete congenital heart block. The risk of complete heart block in anti-Ro/SSA-positive pregnancies is approximately 2 to 4 percent. When it does occur, it can require pacemaker implantation and carries significant morbidity. A previous pregnancy affected by congenital heart block raises the recurrence risk substantially. All women with Sjogren's who are or plan to become pregnant should be tested for anti-Ro/SSA antibodies.[5]

If your antibodies are positive. Women with high-titer anti-Ro/SSA antibodies should receive care from a perinatologist (maternal-fetal medicine specialist) in addition to their rheumatologist. Fetal cardiac monitoring, typically using fetal echocardiography, is recommended during the second trimester when the risk window is highest. Hydroxychloroquine may improve pregnancy outcomes in women with Sjogren's and is generally continued during pregnancy.[1]

Other pregnancy considerations. Do not stop Sjogren's medications on your own if you become pregnant or are trying to conceive. Some medications, including methotrexate, must be stopped before conception and require a planned transition supervised by your rheumatologist. Others, like hydroxychloroquine, are generally safe to continue. If you have antiphospholipid antibodies, hormonal contraception may carry additional risk and should be discussed with your care team.[1]

Disease Relationships

Overlap with other autoimmune diseases

Sjogren's disease frequently coexists with or overlaps other systemic autoimmune conditions. This is one of the main reasons it can be hard to diagnose. The same antibodies, particularly anti-Ro/SSA, can appear in both Sjogren's and lupus, and both conditions share features like fatigue, joint pain, positive ANA, and photosensitive rashes.[3]

Sjogren's and lupus. Lupus is the autoimmune condition most commonly associated with Sjogren's. Patients with both conditions tend to have higher rates of Raynaud phenomenon, arthritis, and central nervous system involvement than those with primary Sjogren's alone. The anti-Ro/SSA antibody is labeled "SSA" for Sjogren's syndrome-associated in many lab reports, which can create confusion; this antibody is not specific to Sjogren's and is found in a significant proportion of lupus patients as well.[4]

Sjogren's and rheumatoid arthritis. RA is the other most commonly associated disease. Sjogren's occurring in someone with RA can make the joint picture more complex, particularly because patients with both Sjogren's and anti-CCP antibodies may develop erosive arthritis requiring more aggressive treatment than typical primary Sjogren's arthritis.[5]

Sjogren's and scleroderma. A small subset of primary Sjogren's patients, about 5 percent, have anticentromere antibodies. These patients tend to have more severe sicca symptoms, features that overlap with limited scleroderma such as Raynaud phenomenon, and may not have anti-Ro/SSA antibodies at all.[4]

Other autoimmune associations. Autoimmune thyroid disease, primary biliary cholangitis, celiac disease, and autoimmune hepatitis all occur at higher rates in Sjogren's patients than in the general population. A diagnosis of Sjogren's does not mean other autoimmune conditions will develop, but awareness of these associations helps ensure that new symptoms receive appropriate investigation rather than being automatically attributed to Sjogren's.[5]

Get updates when new guides are published

Plain-English condition guides, lab explainers, and tools for autoimmune patients.

Common Questions

Questions patients often ask

My eyes and mouth feel fine. Can I still have Sjogren's? ▼

Yes. A small but meaningful proportion of Sjogren's patients, estimated at 5 to 20 percent, present primarily with extraglandular features like neuropathy, interstitial lung disease, or hematologic abnormalities without prominent sicca symptoms. Objective testing can show significant glandular dysfunction even in patients who have adapted to dryness and no longer notice it as a prominent complaint. Dryness being absent or mild does not rule out Sjogren's.[2]

I was told my anti-Ro antibody is "weakly positive." Does that mean I don't have Sjogren's? ▼

A weakly positive anti-Ro/SSA result needs to be interpreted in context. Modern solid-phase immunoassays are highly sensitive but can produce weak positives that are not consistently reproducible across different laboratory platforms. Depending on the rest of the evaluation, your rheumatologist may repeat the test, obtain objective dryness testing, review the assay method, or consider a lip biopsy. A weakly positive result alone is not sufficient to diagnose Sjogren's.[3]

Does Sjogren's get worse over time? ▼

The course of Sjogren's varies considerably between patients. Some people have a stable, relatively mild disease dominated by sicca symptoms throughout their lives. Others develop new extraglandular manifestations or associated autoimmune diseases over time. Studies suggest that new extraglandular involvement or a second autoimmune disease develops in roughly a third to half of patients over 20 to 25 years of follow-up. Glandular function tends to decline slowly, which is why early attention to dental health and residual salivary function matters. There is currently no reliable way to predict early on which patients will develop more systemic disease.[1]

Why is my brain fog not improving with treatment? ▼

Brain fog in Sjogren's is one of the most frustrating symptoms to treat because its cause is often not inflammatory. Many patients have brain fog that is driven by poor sleep (often disrupted by dryness and nocturia), fibromyalgia, depression, or fatigue rather than by active immune-mediated brain inflammation. These underlying contributors do not respond to immunosuppressants. A careful evaluation for sleep disorders, mood disorders, and fibromyalgia is often more productive than escalating immunosuppression. If white matter changes are seen on MRI, these are often related to vascular risk factors or migraine rather than Sjogren's itself.[1]

Should I avoid certain medications? ▼

Yes. Medications with anticholinergic effects are particularly problematic in Sjogren's because they significantly worsen dryness. These include many antihistamines, certain antidepressants (particularly tricyclics), bladder medications such as oxybutynin, many over-the-counter sleep aids, and some cold remedies. When starting a new medication, it is worth checking whether it has anticholinergic effects. This does not necessarily mean the medication cannot be used, but your care team should be aware of the trade-off. Immune checkpoint inhibitor cancer therapies (such as pembrolizumab) can also trigger or worsen a Sjogren's-like sicca syndrome.[1]

Is Sjogren's the same as "dry eye disease"? ▼

No. Dry eye disease is a broad category that includes many causes. Only about 10 percent of people with clinically significant dry eye have Sjogren's. Meibomian gland dysfunction, allergic eye disease, and age-related tear production decline are far more common causes of dry eye. Sjogren's-related dry eye is distinguished by aqueous tear deficiency caused by autoimmune destruction of lacrimal gland tissue, and it is often more severe and more resistant to standard over-the-counter artificial tear therapy than other forms of dry eye.[3]

What is the difference between Sjogren's and lupus? ▼

Both are systemic autoimmune diseases that can share antibodies (especially anti-Ro/SSA), positive ANA, joint pain, and fatigue. The distinctions lie in what defines each disease. Lupus is characterized by multi-system inflammation including kidney disease, blood cell abnormalities, serositis, and CNS involvement. Sjogren's is defined by salivary and lacrimal gland inflammation causing sicca. Anti-dsDNA and anti-Sm antibodies are specific to lupus and not seen in primary Sjogren's. In practice, the conditions can overlap and sometimes co-occur in the same patient. Features that can look very similar early in the course of either disease mean that the diagnosis may require time and ongoing evaluation to become clear.[3,4]

Primary Sources

Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79:3.
Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol 2019; 203:81.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome. Ann Rheum Dis 2017; 76:9.
Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren's syndrome at diagnosis in 8310 patients. Ann Rheum Dis 2017; 76:1042.
Malladi AS, Sack KE, Shiboski SC, et al. Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64:911.
Zero DT, Brennan MT, Daniels TE, et al. Clinical practice guidelines for oral management of Sjogren disease: Dental caries prevention. J Am Dent Assoc 2016; 147:295.
Nocturne G, Mariette X. Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168:317.
Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011; 70:1363.
de Frémont GM, Costedoat-Chalumeau N, Lazaro E, et al. Pregnancy outcomes in women with primary Sjogren's syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol 2023; 5:e330.
Buyon JP, Masson M, Izmirly CG, et al. Prospective Evaluation of High Titer Autoantibodies and Fetal Home Monitoring in the Detection of Atrioventricular Block Among Anti-SSA/Ro Pregnancies. Arthritis Rheumatol 2024; 76:411.
Brito-Zerón P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016; 75:348.
Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 2005; 128:2518.
Lee AS, Scofield RH, Hammitt KM, et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjogren's. Chest 2021; 159:683.
Maciel G, Crowson CS, Matteson EL, Cornec D. Incidence and Mortality of Physician-Diagnosed Primary Sjogren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort. Mayo Clin Proc 2017; 92:734.
Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjogren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2017; 69:517.